These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31319548)

  • 1. Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival.
    Gras Navarro A; Espedal H; Joseph JV; Trachsel-Moncho L; Bahador M; Gjertsen BT; Kristoffersen EK; Simonsen A; Miletic H; Enger PØ; Rahman MA; Chekenya M
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31319548
    [No Abstract]   [Full Text] [Related]  

  • 2. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
    Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
    Lundqvist A; Abrams SI; Schrump DS; Alvarez G; Suffredini D; Berg M; Childs R
    Cancer Res; 2006 Jul; 66(14):7317-25. PubMed ID: 16849582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.
    Gras Navarro A; Kmiecik J; Leiss L; Zelkowski M; Engelsen A; Bruserud Ø; Zimmer J; Enger PØ; Chekenya M
    J Immunol; 2014 Dec; 193(12):6192-206. PubMed ID: 25381437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells.
    Lundqvist A; Yokoyama H; Smith A; Berg M; Childs R
    Blood; 2009 Jun; 113(24):6120-7. PubMed ID: 19202127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors-Human Leukocyte Antigen Ligand Mismatch and Activation Receptor-Ligand Interactions.
    Haspels HN; Rahman MA; Joseph JV; Gras Navarro A; Chekenya M
    Front Immunol; 2018; 9():1345. PubMed ID: 29967607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway.
    Rahman MA; Engelsen AST; Sarowar S; Bindesbøll C; Birkeland E; Goplen D; Lotsberg ML; Knappskog S; Simonsen A; Chekenya M
    Front Cell Dev Biol; 2022; 10():1022191. PubMed ID: 36619857
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
    Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
    Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
    Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
    Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human U87 glioblastoma cells with stemness features display enhanced sensitivity to natural killer cell cytotoxicity through altered expression of NKG2D ligand.
    Oh SJ; Yang JI; Kim O; Ahn EJ; Kang WD; Lee JH; Moon KS; Lee KH; Cho D
    Cancer Cell Int; 2017; 17():22. PubMed ID: 28203118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo.
    Manton CA; Johnson B; Singh M; Bailey CP; Bouchier-Hayes L; Chandra J
    Sci Rep; 2016 Jan; 6():18953. PubMed ID: 26804704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ER stress inducer DMC enhances TRAIL-induced apoptosis in glioblastoma.
    van Roosmalen IAM; Reis CR; Setroikromo R; Yuvaraj S; Joseph JV; Tepper PG; Kruyt FAE; Quax WJ
    Springerplus; 2014; 3(1):495. PubMed ID: 26331107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.
    Loi M; Becherini P; Emionite L; Giacomini A; Cossu I; Destefanis E; Brignole C; Di Paolo D; Piaggio F; Perri P; Cilli M; Pastorino F; Ponzoni M
    J Control Release; 2014 Oct; 192():157-66. PubMed ID: 25041999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
    Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation.
    Heim C; Hartig L; Weinelt N; Moser LM; Salzmann-Manrique E; Merker M; Wels WS; Tonn T; Bader P; Klusmann JH; van Wijk SJL; Rettinger E
    Mol Ther Oncol; 2024 Jun; 32(2):200802. PubMed ID: 38706988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selenium-containing ruthenium complex synergizes with natural killer cells to enhance immunotherapy against prostate cancer via activating TRAIL/FasL signaling.
    Lai H; Zeng D; Liu C; Zhang Q; Wang X; Chen T
    Biomaterials; 2019 Oct; 219():119377. PubMed ID: 31374478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.
    Kozlowska AK; Tseng HC; Kaur K; Topchyan P; Inagaki A; Bui VT; Kasahara N; Cacalano N; Jewett A
    Cancer Immunol Immunother; 2016 Sep; 65(9):1085-97. PubMed ID: 27439500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Comprehensive Gene Expression and NK Cell-Mediated Killing in Glioblastoma Cell Line-Derived Spheroids.
    Morimoto T; Nakazawa T; Matsuda R; Nishimura F; Nakamura M; Yamada S; Nakagawa I; Park YS; Tsujimura T; Nakase H
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer cell therapy potentially enhances the antitumor effects of bevacizumab plus irinotecan in a glioblastoma mouse model.
    Tran TA; Kim YH; Duong TH; Thangaraj J; Chu TH; Jung S; Kim IY; Moon KS; Kim YJ; Lee TK; Lee CW; Yun H; Lee JJ; Lee HJ; Lee KH; Jung TY
    Front Immunol; 2022; 13():1009484. PubMed ID: 36703992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.
    Höring E; Podlech O; Silkenstedt B; Rota IA; Adamopoulou E; Naumann U
    Anticancer Res; 2013 Apr; 33(4):1351-60. PubMed ID: 23564772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.